Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA

PURPOSE: The phase III PROfound study (NCT02987543) evaluated olaparib versus abiraterone or enzalutamide (control) in metastatic castration-resistant prostate cancer (mCRPC) with tumor homologous recombination repair (HRR) gene alterations. We present exploratory analyses on the use of circulating...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsubara, Nobuaki, de Bono, Johann, Olmos, David, Procopio, Giuseppe, Kawakami, Satoru, Ürün, Yüksel, van Alphen, Robbert, Flechon, Aude, Carducci, Michael A., Choi, Young Deuk, Hotte, Sebastien J., Korbenfeld, Ernesto, Kramer, Gero, Agarwal, Neeraj, Chi, Kim N., Dearden, Simon, Gresty, Christopher, Kang, Jinyu, Poehlein, Christian, Harrington, Elizabeth A., Hussain, Maha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811154/
https://www.ncbi.nlm.nih.gov/pubmed/36318705
http://dx.doi.org/10.1158/1078-0432.CCR-21-3577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9811154/
https://www.ncbi.nlm.nih.gov/pubmed/36318705
http://dx.doi.org/10.1158/1078-0432.CCR-21-3577

Ejemplares similares